To discover and develop a new class of
pharmaceutical compounds based on the biological functions of the interactions between
glycoconjugates and their receptors.
GlycoTech was founded in 1991 and remains today as one of the premier
companies focusing on the biological functions and medical applications of
glycoconjugates. The company has established its own research programs and has
developed a large intellectual property portfolio. Through its catalog business,
GlycoTech has also established one of the largest libraries of rare carbohydrate reagents
and technologies worldwide.
GlycoTech has maintained a corporate alliance with Novartis for the past
six years to develop small molecule mimics of carbohydrate ligands as potent antagonists
for the aberrant extravasation of lymphocytes from the bloodstream during
transplantation-induced reperfusion injury.
In addition, licensing agreements were recently established with Chiron
Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor
markers owned by GlycoTech.
Research agreements have also been established with the National
Institutes of Health, the University of Pennsylvania, the University of Rochester, and the
Chicago Institute for Neurosurgery and Neuroresearch.
GlycoTech is actively seeking other pharmaceutical partners and offers
a combined range of expertise focusing on the Glycobiology area. The corporate structure
and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and
avoid the obligations encountered with the fixed financial responsibilities associated
with internal organic growth. We welcome the opportunity to meet with all interested
parties to explore mutually constructive collaborations.
FINE CHEMICALS and REAGENTS BUSINESS
The purpose of this division of GlycoTech is to make techniques and
reagents available to all scientists in order to broaden investigations of carbohydrates
into other fields of research such as Cell Biology, Immunology, Neurobiology, and
Molecular Biology. The first section of the catalog contains some useful protocols written
by well known scientists covering a wide range of topics in Glycobiology. The following
sections contain a variety of unique carbohydrate reagents that allow many of these
protocols to be followed in laboratories not necessarily specializing in Glycobiology.
This catalog also welcomes the participation of scientists within this field with the
objective to actively support their research and discoveries. GlycoTech's long-term goal
is to use our technology and reagents for research towards new discoveries of the
biological functions of carbohydrates based on the interaction of glycoconjugates and
their receptors. We hope that this catalog fulfills these goals and promotes the
application of discoveries to the biomedical community.
Copyright © 1996-99 by GlycoTech Corporation. All rights